Ottawa Hospital Research Institute: Venous Thromboembolism trials

The registry lists 23 Venous Thromboembolism studies with Ottawa Hospital Research Institute as lead sponsor. 7 are open to participants now and 4 have results posted.

Phase 2 6Phase 3 6Phase 4 4No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated ThrombosisRecruitingNCT06894576
• Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein ThrombosisRecruitingNCT06603870Phase 4
• Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)RecruitingNCT06440694Phase 3
• Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous ThromboembolismRecruitingNCT06393868Phase 3
• VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic TherapyRecruitingNCT05920343Phase 2/3
• Primary Thromboprophylaxis in Patients With Malignancy and Central Venous CathetersRecruitingNCT05029063Phase 3
• Statins for Venous Event Reduction in Patients With Venous ThromboembolismRecruitingNCT04319627Phase 3
• Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous ThromboembolismCompletedNCT03266783Phase 4Results posted
• Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot StudyCompletedNCT02559856Phase 4Results posted
• Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis (PREDICTORS)CompletedNCT02297373Results posted
• PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial PilotCompletedNCT01274637Phase 3Results posted
• Venous Thrombosis Virtual Surveillance in COVID-19CompletedNCT04865913
• Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm PatientsCompletedNCT04243122Phase 2
• WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous ThromboembolismTerminatedNCT03297359Phase 2
• StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot StudyStatus unknownNCT02679664Phase 2
• Single Session Percutaneous Mechanical Thrombectomy for the Treatment of Ilio-femoral Deep Vein Thrombosis: A Preliminary EvaluationTerminatedNCT02066597Phase 2
• Apixaban for the Prevention of Venous Thromboembolism in Cancer PatientsCompletedNCT02048865Phase 2
• Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous ThromboembolismCompletedNCT01602445
• Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer PatientsWithdrawnNCT01602432
• Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous ThromboembolismCompletedNCT00967304Phase 4
• Predicting Bleeding Risk on Anticoagulant Therapy for Venous ThromboembolismCompletedNCT00788736
• Screening for Occult Malignancy in Patients With Idiopathic Venous ThromboembolismCompletedNCT00773448Not applicable
• Understanding Risk Factors Involved in Developing a Second Blood Clot.Status unknownNCT00261014